Geneora Pharma (Shijiazhuang) Co. Ltd.
- Address
- Runjiang Headquarters International Building 5th Floor, No. 455 Yuhua East Rd, High-Tech Zone
Sponsor Overview
Specializations
Schizophrenia Research
Geneora Pharma (Shijiazhuang) Co. Ltd. is engaged in clinical research centered on schizophrenia, with attention to treatment options for patients living with this psychiatric disorder. Its trial portfolio reflects interest in therapies intended for symptom management and long-term clinical use in mental health care.
- Schizophrenia treatment
- Psychiatric therapeutics
- Mental health pharmacology
The sponsor’s research activity in this area is focused on clinical evaluation within central nervous system medicine, supporting the development of therapies relevant to antipsychotic care.
Antipsychotic Therapy
The company’s clinical interests include antipsychotic treatment and the assessment of medicines used in psychiatric treatment. Its funded studies indicate a focus on therapeutic options designed for patients requiring sustained management of psychotic symptoms.
- Antipsychotic medicines
- Psychosis management
- Long-acting psychiatric therapies
This area of interest is aligned with the clinical development of treatments used in routine psychiatry practice.
Pharmacokinetics and Bioavailability
Geneora Pharma also shows a clear interest in pharmacokinetic evaluation and bioavailability assessment, particularly for medicines intended for intramuscular injection. These studies support understanding of how treatment exposure is maintained over time in schizophrenia care.
- Pharmacokinetic profiling
- Relative bioavailability
- Injectable formulations
Its research activity in this domain connects drug delivery with clinical use in psychiatric medicine.
Central Nervous System Therapeutics
The sponsor’s trial portfolio falls within central nervous system therapeutics, with emphasis on medicines used to address severe neuropsychiatric illness. The research focus indicates involvement in clinical areas where treatment continuity and exposure consistency are important.
- Neuropsychiatric treatment
- Psychiatric medicine
- Long-term symptom control
These activities place the sponsor within the therapeutic landscape of brain health and mental disorder management.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of the Relative Bioavailability of LY03010 Compared to Paliperidone Palmitate After Intramuscular Injection in Healthy Subjects |  Portugal | Not Recruiting |
| Pharmacokinetic Evaluation of LY03010 and Its Relative Bioavailability Compared to Paliperidone Palmitate in Schizophrenia Patients |  Bulgaria Croatia Portugal | Not Yet Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 18 sites across their trial portfolio.
Therapeutic Focus
- 1.Mental Disorders1 trial150 other sponsors
- 2.Nervous System Diseases1 trial449 other sponsors
Partnered Research Centres
18 centres- Address
- Hospital Da Prelada 0 Floor And 3 rd Floor, Rua Sarmento De Beires 153, 4250-449 Porto
- Address
- Lugar De Sete Fontes S Victor, 4710-243 Braga
- Address
- Complex Lazur, Lake Park, 8001 Burgas
- Address
- Belasita Str 1, 3000 Vratsa
- Address
- Ulitsa Buzludzha 1, 5000 Veliko Tirnovo
- Address
- Jankomir 11, Zagreb, 10000 Zagreb
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Geneora Pharma (Shijiazhuang) Co. Ltd..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.